OrbiMed’s Whitehawk Therapeutics WHWK Stock Holding History

OrbiMed’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18M	Sell	3,934,296 -231,704	-6%	-$964K	0.33%	69
2026 Q1	$14.4M	Hold	4,166,000	–	–	0.28%	67
2025 Q4	$10.1M	Hold	4,166,000	–	–	0.21%	81
2025 Q3	$7.92M	Hold	4,166,000	–	–	0.19%	77
2025 Q2	$7.79M	Hold	4,166,000	–	–	0.19%	67
2025 Q1	$7.42M	Buy	+4,166,000	New	+$10.9M	0.18%	71
2022 Q1	–	Sell	-127,600	Closed	-$3.08M	–	164
2021 Q4	$3.08M	Sell	127,600 -218,662	-63%	-$5.49M	0.04%	145
2021 Q3	$10.2M	Sell	346,262 -1	-0%	-$30	0.11%	126
2021 Q2	$8.78M	Hold	346,263	–	–	0.09%	132
2021 Q1	$6.7M	Hold	346,263	–	–	0.06%	133
2020 Q4	$5.09M	Hold	346,263	–	–	0.04%	140
2020 Q3	$7.79M	Hold	346,263	–	–	0.1%	114
2020 Q2	$6.49M	Hold	346,263	–	–	0.09%	112
2020 Q1	$2.86M	Hold	346,263	–	–	0.05%	119
2019 Q4	$3.24M	Hold	346,263	–	–	0.05%	112
2019 Q3	$3.53M	Hold	346,263	–	–	0.07%	100
2019 Q2	$4.73M	Hold	346,263	–	–	0.07%	113
2019 Q1	$4.68M	Hold	346,263	–	–	0.07%	110
2018 Q4	$8.83M	Hold	346,263	–	–	0.16%	91
2018 Q3	$16M	Hold	346,263	–	–	0.19%	96
2018 Q2	$21.6M	Buy	+346,263	New	+$20.9M	0.26%	87

Other funds holding WHWK

Yu Fan $108M AUM 137.54% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $136M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

OrbiMed's WHWK Position: Q2 2026 in Review

OrbiMed reduced its Whitehawk Therapeutics (WHWK) stake by 5.6% in Q2 2026, selling an estimated $964K and leaving 3,934,296 shares worth $18M. The position accounts for 0.33% of the portfolio, ranked #69.

OrbiMed first reported a position in WHWK in Q2 2018 and has held it in 21 quarters since. The position peaked at $21.6M in Q2 2018. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

OrbiMed held 3,934,296 shares of Whitehawk Therapeutics worth $18M as of Q2 2026.
OrbiMed sold 231,704 Whitehawk Therapeutics shares in Q2 2026, an estimated $964K.
Whitehawk Therapeutics made up 0.33% of OrbiMed's portfolio in Q2 2026, its #69 holding.
OrbiMed first reported a position in Whitehawk Therapeutics in Q2 2018 and has held it in 21 quarters since.
OrbiMed's Whitehawk Therapeutics position peaked at $21.6M in Q2 2018.
77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.